CNBX - Cannabics Pharmaceuticals Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Cannabics Pharmaceuticals Inc.

#3 Bethesda Metro Center
Suite 700
Bethesda, MD 20814
United States

Full Time Employees8

Key Executives

NameTitlePayExercisedYear Born
Mr. Eyal BaradCo-Founder, CEO & Director206.95kN/A1965
Dr. Eyal Ballan Ph.D.Co-founder, CTO & Director255.03kN/A1976
Mr. Uri Ben-Or CPA, M.B.A., CPA, MBACFO & Principal Accounting OfficerN/AN/A1970
Mr. David E. PriceSec. & Corp. CounselN/AN/A1965
Mr. Yasha BorsteinChief Data OfficerN/AN/A1963
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cannabics Pharmaceuticals Inc., an early stage biotechnology company, engages in the development and licensing of cannabinoid-based treatments and therapies. The company focuses on developing and marketing therapies and biotechnological tools for the relief from various ailments that respond to active ingredients sourced from the cannabis plant. It offers Cannabics SR, a medical cannabis capsules to treat cancer related cachexia/anorexia syndrome in advanced cancer patients. The company also focuses on the commercialization of a diagnostic test based on liquid biopsies of patients suffering from epithelial cancers; and development of diagnostics that monitor cancer progression and cannabinoid cancer sensitivity tests for the treatment of cancer with cannabinoid medicine. Cannabics Pharmaceuticals Inc. has a collaboration with SIMFO GmbH for circulating tumor cell drug sensitivity tests. The company was formerly known as American Mining Corporation and changed its name to Cannabics Pharmaceuticals Inc. in May 2014. Cannabics Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. Cannabics Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.

Corporate Governance

Cannabics Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.